Effects of a Combination of Recombinant Human Growth Hormone with Metformin on Glucose Metabolism and Body Composition in Patients with Metabolic Syndrome

 

 Buy Article Permissions and Reprints

Abstract

Abdominal obesity and insulin resistance are central findings in metabolic syndrome. Since treatment with recombinant human growth hormone (rhGH) can reduce body fat mass in patients with organic GH deficiency, rhGH therapy may also have favourable effects on patients with metabolic syndrome. However, due to the highly increased risk for type 2 diabetes in these patients, strategies are needed to reduce the antagonistic effect of rhGH against insulin. We conducted a 18-month randomised, double-blind, placebo-controlled study to assess the effect of rhGH in combination with metformin (Met) in patients with metabolic syndrome. 25 obese men (55 ± 6 years, BMI 33.4 ± 2.9 kg/m²) with mildly elevated fasting plasma glucose (FPG) levels at screening (6.1 - 8.0 mmol/l) were included. All patients received metformin (850 mg twice daily) either alone or in combination with rhGH (daily dose 9.5 μg/kg body weight). An oGTT was performed at baseline, after 6 weeks, and after 3, 6, 12, and 18 months of therapy. Glucose disposal rate (GDR) was measured by euglycemic hyperinsulinemic clamp at 0 and 18 months and body composition was measured by DEXA every 6 months. In the Met + GH group, IGF-I increased from 146 ± 56 μg/l to 373 ± 111 μg/l (mean ± SD) after 3 months and remained stable after that. BMI did not change significantly in either group during the study. Total body fat decreased by -4.3 ± 5.4 kg in the Met + GH group and by -2.7 ± 2.9 kg in the Met + Placebo group (differences between the two groups: p = n. s.). Waist circumference decreased in both groups (Met + GH: 118 ± 8 cm at baseline, 112 ± 10 cm after 18 months; Met + Placebo: 114 ± 7 cm vs. 109 ± 8 cm; differences between the two groups: p = 0.096). In the Met + GH group, FPG increased significantly after 6 months (5.9 ± 0.7 vs. 6.7 ± 0.4 mmol/l; p = 0.005), but subsequently decreased to baseline levels (18 months: 5.8 ± 0.2 mmol/l). FPG remained stable in the Met + Placebo group until 12 months had elapsed, and then slightly decreased (baseline: 6.2 ± 0.3, 18 months: 5.5 ± 0.6 mmol/l, p = 0.02). No significant changes were seen in either group regarding glucose and insulin AUC during oGTT or HbA_1c levels. GDR at 18 months increased by 20 ± 39 % in Met + GH-group and decreased by -11 ± 25 % in the Met + Placebo group (differences between the two groups: p = 0.07). In conclusion, treatment of patients with metabolic syndrome and elevated FPG levels did not cause sustained negative effects on glucose metabolism or insulin sensitivity if given in combination with metformin. However, since our data did not show significant differences between the two treatment groups with respect to body composition or lipid metabolism, future studies including larger numbers of patients will have to clarify whether the positive effects of rhGH on cardiovascular risk factors that have been shown in patients with GH deficiency are also present in patients with metabolic syndrome, and are additive to the effects of metformin.

References

• 1 Reaven G M. Banting lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1988;  37 1595-1607
  CrossrefPubMedGoogle Scholar
• 2 Rosen T, Eden S, Larson G, Wilhelmsen L, Bengtsson B A. Cardiovascular risk factors in adult patients with growth hormone deficiency.  Acta Endocrinol (Copenh). 1993;  129 195-200
  PubMedGoogle Scholar
• 3 Johannsson G, Marin P, Lonn L. et al . Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.  J Clin Endocrinol Metab. 1997;  82 727-734
  CrossrefPubMedGoogle Scholar
• 4 Johannsson G, Bengtsson B A. Growth hormone and metabolic syndrome.  J Endocrinol Invest. 1999;  22 41-46
  PubMedGoogle Scholar
• 5 Franco C, Bengtsson B A, Johannsson G. Visceral obesity and the role of the somatotropic axis in the development of metabolic complications.  Growth Horm IGF Res. 2001;  11 Suppl A S97-S102
  PubMedGoogle Scholar
• 6 Bjorntorp P, Rosmond R. Neuroendocrine abnormalities in visceral obesity.  Int J Obes Relat Metab Disord. 2000;  24 Suppl 2 S80-S85
  CrossrefPubMedGoogle Scholar
• 7 Bjorntorp P. Neuroendocrine abnormalities in human obesity.  Metabolism. 1995;  44 (2 Suppl 2) 38-41
  CrossrefPubMedGoogle Scholar
• 8 Veldhuis J D, Liem A Y, South S. et al . Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay.  J Clin Endocrinol Metab. 1995;  80 3209-3222
  CrossrefPubMedGoogle Scholar
• 9 Veldhuis J D, Iranmanesh A, Weltman A. Elements in the pathophysiology of diminished growth hormone (GH) secretion in aging humans.  Endocrine. 1997;  7 41-48
  PubMedGoogle Scholar
• 10 Weltman A, Weltman J Y, Veldhuis J D, Hartman M L. Body composition, physical exercise, growth hormone and obesity.  Eat Weight Disord. 2001;  6 (3 Suppl) 28-37
  PubMedGoogle Scholar
• 11 Pijl H, Langendonk J G, Burggraaf J. et al . Altered neuroregulation of GH secretion in viscerally obese premenopausal women.  J Clin Endocrinol Metab. 2001;  86 5509-5515
  CrossrefPubMedGoogle Scholar
• 12 Marin P, Kvist H, Lindstedt G, Sjostrom L, Bjorntorp P. Low concentrations of insulin-like growth factor-I in abdominal obesity.  Int J Obes Relat Metab Disord. 1993;  17 83-89
  PubMedGoogle Scholar
• 13 Amato G, Mazziotti G, Di Somma C. et al . Recombinant growth hormone (GH) therapy in GH-deficient adults: a long- term controlled study on daily versus thrice weekly injections.  J Clin Endocrinol Metab. 2000;  85 3720-3725
  CrossrefPubMedGoogle Scholar
• 14 Feldt-Rasmussen U, Abs R, Bengtsson B A. et al . Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing’s disease.  Eur J Endocrinol. 2002;  146 67-74
  CrossrefPubMedGoogle Scholar
• 15 Fowelin J, Attvall S, von Schenck H, Smith U, Lager I. Characterization of the insulin-antagonistic effect of growth hormone in insulin-dependent diabetes mellitus.  Diabet Med. 1995;  12 990-996
  CrossrefPubMedGoogle Scholar
• 16 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
  CrossrefPubMedGoogle Scholar
• 17 Knowler W C, Barrett-Connor E, Fowler S E. et al . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
  CrossrefPubMedGoogle Scholar
• 18 National Institutes of Health. Third report of the National Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary. Bethesda MD,. National Institutes of Health, National Heart, Lung and Blood Institute 2001: No 01-3670
  Google Scholar
• 19 Alberti K G, Zimmet P Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus, provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
  CrossrefPubMedGoogle Scholar
• 20 DeFronzo R A, Gunnarsson R, Bjorkman O, Olsson M, Wahren J. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus.  J Clin Invest. 1985;  76 149-155
  CrossrefPubMedGoogle Scholar
• 21 DeFronzo R A, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease.  Diabetes Care. 1991;  14 173-194
  CrossrefPubMedGoogle Scholar
• 22 Sugimoto M, Takeda N, Hattori J. et al . Pharmacological treatments for GH-induced insulin resistance.  Endocr J. 1999;  46 Suppl S51-S53
  PubMedGoogle Scholar
• 23 Richelsen B. Effect of growth hormone on adipose tissue and skeletal muscle lipoprotein lipase activity in humans.  J Endocrinol Invest. 1999;  22 10-15
  PubMedGoogle Scholar
• 24 Johannsson G, Karlsson C, Lonn L. et al . Serum leptin concentration and insulin sensitivity in men with abdominal obesity.  Obes Res. 1998;  6 416-421
  PubMedGoogle Scholar
• 25 Kay J P, Alemzadeh R, Langley G, D’Angelo L, Smith P, Holshouser S. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.  Metabolism. 2001;  50 1457-1461
  CrossrefPubMedGoogle Scholar
• 26 Chu N V, Kong A P, Kim D D. et al . Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.  Diabetes Care. 2002;  25 542-549
  PubMedGoogle Scholar
• 27 Wulffele M G, Kooy A, De Zeeuw D, Stehouwer C D, Gansevoort R T. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus; a systematic review.  Br J Clin Pharmacol. 2002;  53 549P-550P
  CrossrefPubMedGoogle Scholar
• 28 Bengtsson B A, Brummer R J, Bosaeus I. Growth hormone and body composition.  Horm Res. 1990;  33 (Suppl 4) 19-24
  PubMedGoogle Scholar
• 29 Bengtsson B A. The consequences of growth hormone deficiency in adults.  Acta Endocrinol (Copenh). 1993;  128 Suppl 2 2-5
  PubMedGoogle Scholar
• 30 Beshyah S A, Freemantle C, Shahi M. et al . Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults.  Clin Endocrinol (Oxf). 1995;  42 73-84
  PubMedGoogle Scholar
• 31 Johnston D G, Al-Shoumer K A, Chrisoulidou A, Kousta E, Beshyah S, Robinson S. Long-term effects of growth hormone therapy on intermediary metabolism and insulin sensitivity in hypopituitary adults.  J Endocrinol Invest. 1999;  22 37-40
  PubMedGoogle Scholar
• 32 Johannsson G, Oscarsson J, Rosen T. et al . Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-deficient adults. Influence of gender and Apo(a) and ApoE phenotypes.  Arterioscler Thromb Vasc Biol. 1995;  15 2142-2150
  PubMedGoogle Scholar
• 33 Binnerts A, Swart G R, Wilson J H. et al . The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition.  Clin Endocrinol (Oxf). 1992;  37 79-87
  CrossrefPubMedGoogle Scholar
• 34 Eden S, Wiklund O, Oscarsson J, Rosen T, Bengtsson B A. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations.  Arterioscler Thromb. 1993;  13 296-301
  PubMedGoogle Scholar
• 35 Vermeulen A, Goemaere S, Kaufman J M. Testosterone, body composition and aging.  J Endocrinol Invest. 1999;  22 110-116
  PubMedGoogle Scholar
• 36 Marin P, Arver S. Androgens and abdominal obesity.  Baillieres Clin Endocrinol Metab. 1998;  12 441-451
  CrossrefPubMedGoogle Scholar
• 37 Lamberts S W, van den Beld A W, van der Lely A J. The endocrinology of aging.  Science. 1997;  278 419-424
  CrossrefPubMedGoogle Scholar
• 38 Ozata M, Oktenli C, Bingol N, Ozdemir I C. The effects of metformin and diet on plasma testosterone and leptin levels in obese men.  Obes Res. 2001;  9 662-667
  CrossrefPubMedGoogle Scholar
• 39 Oleandri S E, Maccario M, Rossetto R. et al . Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity.  J Endocrinol Invest. 1999;  22 134-140
  CrossrefPubMedGoogle Scholar
• 40 Juul A, Andersson A M, Pedersen S A. et al . Effects of growth hormone replacement therapy on IGF-related parameters and on the pituitary-gonadal axis in GH-deficient males. A double- blind, placebo-controlled crossover study.  Horm Res. 1998;  49 269-278
  CrossrefPubMedGoogle Scholar

B. L. Herrmann, M. D.

Division of Endocrinology · Centre of Internal Medicine · University of Essen ·

Hufelandstr. 55 · 45122 Essen · Germany

Phone: +49(201)7232821

Fax: +49(2017235972 ·

Email: burkhard.herrmann@uni-essen.de